Slide 1: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference January 15, 2026 NASDAQ: PGEN
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek
Slide 3: Precigen company overview
Precigen is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat APPROACH diseases with high unmet patient need. Precigen’s approach unites cutting-edge technology, precise indication selection, and smart regulat
Slide 4: AdenoVerse®
AdenoVerse® Novel, Industry-Leading Viral Vector Platform Product Target Indication Phase 1 Phase 2 Phase 3 Approved PAPZIMEOS HPV 6/11 RRP Underpinned by innovative, proprietary AdenoVerse® platform Novel platform to train and amplify the immune PRGN-2009 OPSCC/ system in vivo (from WITHIN the body
Slide 5: A Transformational Year for Precigen – Now a Commercial-Stage Biotech
Full FDA-approval for PAPZIMEOS for the treatment 1 of all adults with RRP regardless of disease severity 2 Commenced commercial US launch of PAPZIMEOS 2025: A Transformational 3 Launched the commercial manufacturing Year for Precigen – campaign for PAPZIMEOS Now a Commercial- Stage Biotech 4 First
Slide 6: The Only FDA-approved Option for Adults with Recurrent Respiratory Papillomatosis (RRP)
The Only FDA-approved Option for Adults with Recurrent Respiratory Papillomatosis (RRP) • RRP is a rare, debilitating disease of the respiratory tract caused by HPV 6 or HPV 11 infection • RRP was previously managed mainly by surgical interventions; repeat surgeries are associated with significant m
Slide 7: PAPZIMEOS: From IND in 2021 to Full FDA Approval in 2025
PAPZIMEOS: From IND in 2021 to Full FDA Approval in 2025 FDA Full Approval Commercialization First market: US ODD - EU 1st BTD for RRP Phase 1 data IND clearance presentation Pivotal data - ASCO 1st to receive FDA accelerated Phase 1 start approval pathway BLA submission Phase 2 start ODD - US 2021
Slide 8: PAPZIMEOS has the potential to be the standard of care for adults with RRP
First-and-only FDA-approved therapy for the treatment of adults with RRP First-and-only FDA-approved RRP Chronic, debilitating Ability to be utilized Transformative treatment to target rare disease with across different clinical benefit underlying cause of high unmet need sites of care disease PAPZI
Slide 9: PAPZIMEOS Pivotal Clinical Data
PAPZIMEOS Pivotal Clinical Data 9
Slide 10: PAPZIMEOS Targets the Root Cause of RRP
PAPZIMEOS Targets the Root Cause of RRP • Ability for repeat injections • Designed to generate an immune response directed against papilloma cells expressing HPV 6 or HPV11 Actual patient Same patient before treatment after treatment PAPZIMEOS is administered to 1 patient via subcutaneous injection
Slide 11: PAPZIMEOS Has Demonstrated Robust Clinical Data to Date
PAPZIMEOS Has Demonstrated Robust Clinical Data to Date as Evidenced by Durable Ongoing Responses Efficacy: 51% Complete Response Rate Durable, Ongoing Complete Responses Pre-treatment Post-treatment Post-Treatment 12-months p=<0.0001 12-months 10 0 Pre-Tx YEAR 1 YEAR 2 YEAR 3 8 0 3 8 0 8 0 4 5 0 4
Slide 12: Commercial Opportunity and Launch Momentum
Commercial Opportunity and Launch Momentum 12
Slide 13: The Prevalence of RRP in the US and Rest of World Suggests Multi-billion-dollar Revenue Potential
The Prevalence of RRP in the US and Rest of World Suggests Multi-billion-dollar Revenue Potential Prevalence of RRP in US1 Prevalence of RRP ex-US2 Approximately Approximately Approximately Approximately 27,000 35,000 50,000 85,000 adult patients adults in EU 4, adults in rest of EU and adults in in
Slide 14: Strong Indicators of Success to Support a Successful Launch Pre-approval
Strong Indicators of Success to Support a Successful Launch Pre-approval Confirm market Claims and EHR analysis identified opportunity ~27,000 patients in the US Optimize footprint/ Pre-approval deployment of Medical, Payer targeting and Sales Leadership teams Build awareness Extensive PIE process,
Slide 15: Strong Indicators of Success to Support a Successful Launch Post-approval
Strong Indicators of Success to Support a Successful Launch Post-approval Full promotional Formulary/IDN and campaign Payer pull through Patient support community support roll-out >96% target center >50 accounts have Medicare and >200 patients coverage within 3 months prescribed PAPZIMEOS: Medicaid
Slide 16: Significant Increase in PAPZIMEOS Brand Awareness Since Approval
Significant Increase in PAPZIMEOS Brand Awareness Since Approval Across Academic and Community Settings Unaided Awareness of PAPZIMEOS (% of Respondents) • Rapid increase in unaided Q3 '25 Q4 '25 brand awareness • Seen across academic and 66% community settings 58% • Reflective of the sense of urgen
Slide 17: Looking Ahead
Looking Ahead PRECIGEN
Slide 18: 2026: Anticipated Milestones for the Year Ahead
2026: Anticipated Milestones for the Year Ahead Continue execution and expansion to Initiate PAPZIMEOS Platform expansion PAPZIMEOS maximize PAPZIMEOS pediatric RRP study in through PRGN-2009 regulatory expansion market opportunity the US to support in head and neck and to the EU and Japan and achie
Slide 19: Strong Foundation for Long-term Value Creation
Leadership team PAPZIMEOS, the De-risked with a proven track first-and-only FDA- technology Advancing record of success Strong balance approved product platform; advancing PAPZIMEOS through discovery, sheet and capital for RRP, launched in portfolio of towards regulatory development, efficient opera
Slide 20: Q&A
y : oJ Papzimeos” Zopapogene imadenovec-drba Q&A PRECIGEN
Slide 21: PRECIG
Ss PRECIG =| =N